Ovcina-Kurtovic Nermina, Kasumagic-Halilovic Emina
Department of Dermatovenerology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina.
Mater Sociomed. 2022 Mar;34(1):40-43. doi: 10.5455/msm.2022.33.40-43.
Psoriasis can be described as a T-cell-mediated disease, with a complex role for variety of cytokines and other factors. Among the inflammatory molecules influencing the keratinocites, TNF-α appears critical in sustaining most of the clinical manifestations of psoriasis. It is postulated that changes in cytokine production both locally and systemically could be useful in monitoring disease activity.
The aim of the study was to evaluate serum levels of tumor necrosis factor alpha (TNF-α) in patients with psoriasis and the healthy subjects, and also to assess a possible association between TNF-α, clinical type and severity of disease.
We studied the levels of serum TNF-α in 60 patients with psoriasis and in the serum of helthy 20 controls. According to the clinical type of disease, patients with psoriasis were divided into four groups: chronic plaque psoriasis (CPP), erythrodermic psoriasis (EP), pustular psoriasis (PP) and psoriatic arthritis (PA). Blood samples were collected from all psoriasis patients and from healthy control subjects. Serum level of TNF-α were measured by an enzyme-linked immunosorbent assay (ELISA) technique. The severity of CPP was assessed by Psoriasis Area and Severity Index (PASI).
Serum levels of TNF-α in patients with psoriasis were significialy higher than in the control group (3.25+1.74 pg/mL vs 0.20+0.01pg/mL, respectively). Significantly elevated serum TNF-α was in patients with PP type (7.39+6.92 pg/mL). There was statistically significant difference between the mean level of TNF-ɑ compared to the clinical type of psoriasis (p<0.05). The mean PASI score in patients with CPP was 0.56±12.45. It was not found statistically significant correlation between serum level of TNF-ɑ and PASI score in patients with CPP (p>0,05).
Our results have demonstrated the imortance of determining serum levels of TNF-ɑ in patients with psoriasis. Further investigations are required to clarify the pathogenic role and clinical significance of TNF-ɑ, and these findings may provide important clues to assist in the development of new therapeutic strategies for patients with psoriasis.
银屑病可被描述为一种T细胞介导的疾病，多种细胞因子和其他因素发挥着复杂作用。在影响角质形成细胞的炎症分子中，肿瘤坏死因子-α（TNF-α）似乎在维持银屑病的大多数临床表现方面起着关键作用。据推测，局部和全身细胞因子产生的变化可能有助于监测疾病活动。
本研究旨在评估银屑病患者和健康受试者血清中肿瘤坏死因子-α（TNF-α）的水平，并评估TNF-α与疾病临床类型和严重程度之间的可能关联。
我们研究了60例银屑病患者和20例健康对照者血清中TNF-α的水平。根据疾病的临床类型，银屑病患者分为四组：慢性斑块状银屑病（CPP）、红皮病型银屑病（EP）、脓疱型银屑病（PP）和银屑病关节炎（PA）。采集所有银屑病患者和健康对照者的血样。采用酶联免疫吸附测定（ELISA）技术测定血清TNF-α水平。通过银屑病面积和严重程度指数（PASI）评估CPP的严重程度。
银屑病患者血清TNF-α水平显著高于对照组（分别为3.25+1.74 pg/mL和0.20+0.01 pg/mL）。PP型患者血清TNF-α显著升高（7.39+6.92 pg/mL）。与银屑病临床类型相比，TNF-α平均水平存在统计学显著差异（p<0.05）。CPP患者的平均PASI评分为0.56±12.45。未发现CPP患者血清TNF-α水平与PASI评分之间存在统计学显著相关性（p>0.05）。
我们的结果证明了测定银屑病患者血清TNF-α水平的重要性。需要进一步研究以阐明TNF-α的致病作用和临床意义，这些发现可能为协助开发银屑病患者新的治疗策略提供重要线索。
